Patent ID: 8361980
Filing Date: 2013-01-29
Classification: A61P,C12N

Abstract:
1. A method of lowering of the activity of miR122 in vivo in a primate, comprising administering to the primate at least two successive effective doses of an antisense oligonucleotide targeting miR122, wherein (a) the antisense oligonucleotide is essentially incapable of recruiting RNAseH, (b) the antisense oligonucleotide comprises at least one LNA nucleotide analogue monomer, and (c) the antisense oligonucleotide comprises a fully phosphorothioated backbone, and wherein the at least two successive effective doses of the antisense oligonucleotide are administered to the primate with a time interval of at least two weeks between the doses, and an effective target tissue concentration of the antisense oligonucleotide is maintained between the doses.